ANORO IMPROVED HEALTH-RELATED QUALITY OF LIFE VS PLACEBO, AS MEASURED BY THE SGRQ8,9
On this page:
On this page:
On this page:
Studied in patients with moderate or worse COPD (GOLD 2-4).8,9


ANORO demonstrated an improvement in health-related quality of life vs placebo as measured by a decrease from baseline in mean SGRQ total score of:
- -5.51 unit difference (-8.07 vs -2.56)8†
- -4.03 unit difference (-6.15 vs -2.12)9§
*Defined as a decrease of at least 4 units from baseline.
†Compared with placebo on Day 168; not adjusted for multiplicity.
‡Compared with placebo on Day 84; not adjusted for multiplicity.
§Compared with placebo on Day 84 (P < 0.001).